Metastatic Glucagonoma Presenting with Weight Loss and Necrolytic Migratory Erythema
Keywords:
glucagonoma, glucagonoma syndrome, alpha-cell tumor, Necrolytic Migratory ErythemaAbstract
A 42-year-old Filipino female was admitted due to weight loss and recurrent abdominal pain over the past ten years. In 2010, she was diagnosed to have disseminated PTB associated with a liver mass. After 1 year of anti-TB treatment, lung condition was treated but her liver mass has enlarged. She also developed diarrhea, diabetes, and skin lesions with biopsy results showing Necrolytic Migratory Erythema (NME). CT scan showed liver and pancreatic tumors that were biopsied revealing a neuroendocrine tumor. Blood glucagon level was elevated. She was treated as a case of glucagon-secreting tumor with liver metastases with Everolimus and Octreotide. After 3 months of treatment, she gained weight, the skin lesions improved, and the liver mass decreased in size.
Many of the initial symptoms of glucagonoma are nonspecific and subtle. As a result, glucagonoma is often diagnosed relatively late in the course of the disease. NME, the characteristic skin lesion of the glucagonoma syndrome, is often the clue that leads to the correct diagnosis.
Downloads
References
Frankton S, Bloom SR. Gastrointestinal endocrine tumours. Glucagonomas. Baillières Clin Gastroenterol. 1996;10(4):697-705. http://dx.doi.org/10.1016/S0950-3528(96)90019-6.
Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Llyod RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75(2):53-63.
Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3):458–511. http://dx.doi.org/10.1210/er.2003-0014.
Shi W, Liao W, Mei X, Xiao Q, Zeng Y, Zhou Q. Necrolytic migratory erythema associated with glucagonoma syndrome. J Clin Oncol. 2010;28(20):e329-e331. http://dx.doi./org/10.1200/JCO.2009.25.7113.
Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009;38(3):255-8. http://dx.doi.org/10.1097/MPA. 0b013e3181917e4e.
Vinik AI, Woltering EA, Warner RR et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-34. http;//dx.doi.org/10.1097/MPA.0b013e3131ebaffd.
Van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: A clinical review. Eur J Endocrinol. 2004;151:531-37. http://dx.doi.org/10.1530/eje.0.1510531.
Economopoulos P, Christopoulos C. Glucagonoma. Ann Gastroenterol. 2001; 14(2):99-108.
Kindmark H, Sundin A, Granberg D at al. Endocrine panrceatic tumors with glucagon hypersecretion: A retrospective study of 23 cases during 20 years. Med Oncol. 2007; 24(3):330-7. http://dx.doi.org/10.1007/s12032-007-0011-2.
Kulke, MH et al. NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735-752. http://dx.doi.org/10.1097/MPA.0b013e3181ebb168.
Ramage JK, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumour (NETs)s. Gut. 2012; 61(1):6-32. http://dx.doi.org/10.1136/gutjnl-2011-300831.
Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19(10):1727-33. http://dx.doi.org/10.1093/annonc/mdn351.
Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152(1):107-113. http://dx.doi.org/10.1016/j.surg.2012.02.011.
Published
How to Cite
Issue
Section
License
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
